Nephrogenic Systemic Fibrosis

400 mg, one tablet daily for 12 or 24 weeks

Imatinib mesylate (Glivec)

Department of Dermatology

Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec

An Open Label Clinical Trial of Imatinib Mesylate(Glivec)in Patients With Moderate to Severe Nephrogenic Systemic Fibrosis

University of Aarhus

Imatinib mesylate 400 milligrams (mg) orally once daily for 4 months. Dosage was reduced to 200 mg if the participant developed gastrointestinal intolerance or alopecia.

Imatinib mesylate 400 mg orally once daily for 4 months. Dosage was reduced to 200 mg if the participant developed gastrointestinal intolerance or alopecia.

Imatinib Mesylate Treatment

Sex: Female, Male

The modified Rodnan Skin Score is the accepted clinical measure of scleroderma skin activity. The investigator assessed the thickening of the skin using the modified Rodnan Skin Score through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Skin thickness was assessed on a scale of 0 to 3; 0 representing normal skin and 3 being severe thickening. The sum of the individual scores can range from 0 (normal) to 51 (severe thickening in all 17 areas). Percentage change is calculated as the Month 4 Score - Baseline Score/Baseline Score * 100. A negative percentage change indicates improvement.

Percentage Change From Baseline in the Modified Rodnan Skin Score (mRSS) to Assess Skin Tethering

Change From Baseline in Maximal Extension of Elbows and Knees

Change From Baseline in Histologic Appearance of Skin Biopsy

Change From Baseline in Visual Analog Scale (VAS) for Pain

Change From Baseline in Health Assessment Questionnaire (HAQ) Score

Change From Baseline in Short Form 36 (SF-36) Score

Imatinib mesylate 400 mg orally once daily for 4 months. Dosage was reduced to 200 mg if participant developed gastrointestinal intolerance or alopecia.

Overall Study

Jonathan Kay, MD

400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants develop gastrointestinal intolerance or alopecia.

Imatinib mesylate

Massachusetts General Hospital

Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis

An Open Label Phase 2 Pilot Study to Determine the Safety, Efficacy and Tolerability of Gleevec (Imatinib Mesylate) in the Treatment of Nephrogenic Systemic Fibrosis

Principal Investigator

Novartis Pharmaceuticals

nephrogenic fibrosing dermopathy

tyrosine

nephrogenic fibrosing dermopathy/tyrosine

Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec

Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu